The Trump administration exempted India's pharmaceutical sector from reciprocal tariffs, recognizing its crucial role in supplying affordable medicines globally. This decision highlights the importance of cost-effective generic drugs and strengthens the US-India trade relationship, although potential future challenges remain.
